Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use

Carcinogenesis

Volumn 28, Issue 10, 2007, Pages 2139-2142

  Chu, William ^a   Fyles, Anthony ^a   Sellers, Edward M ^a   Mccready, David R ^a   Murphy, Joan ^a   Pal, Tuya ^b   Narod, Steven A ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CYTOCHROME P450; CYTOCHROME P450 3A4; DRUG METABOLITE; GENOMIC DNA; NORTAMOXIFEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ALLELE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG METABOLISM; ENDOMETRIUM CANCER; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; BREAST NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; ENDOMETRIAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; ODDS RATIO; ONTARIO; POSTMENOPAUSE; PREMENOPAUSE; REGISTRIES; RETROSPECTIVE STUDIES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 34648869895     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm087     Document Type: Article

References (61)

1. EBCTCG. (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet, 365, 1687-1717.
2. Fisher,B. et al. (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet, 353, 1993-2000.
3. Fisher,B. et al. (2005) Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst., 97, 1652-1662.
4. Fornander,T. et al. (1989) Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet, 1, 117-120.
5. Fisher,B. et al. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl Cancer Inst., 86 527-537.
6. Fisher,B. et al. (1998) Tamoxifen for Prevention of Breast Cancer Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst., 90, 1371-1388.
7. Rutqvist,L.E. et al. (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J. Natl Cancer Inst., 87, 645-651.
8. Curtis,R.E. et al. (1996) Second cancers after adjuvant tamoxifen therapy for breast cancer. J. Natl Cancer Inst., 88, 832-834.
9. Curtis,R.E. et al. (2004) Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J. Natl Cancer Inst., 96, 70-74.
10. van Leeuwen,F.E. et al. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet, 343, 448-452.
11. Mignotte,H. et al. (1998) Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int. J. Cancer, 76, 325-330.
12. Bernstein,L. et al. (1999) Tamoxifen therapy, for breast cancer and endometrial cancer risk. J. Natl Cancer Inst., 91, 1654-1662.
13. Guengerich,F.P. et al. (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a'prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 261, 5051-5060.
14. Guengerich,F.P. (1988) Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol. Pharmacol., 33, 500-508.
15. Bork,R.W. et al. (1989) Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J. Biol. Chem., 264, 910-919.
16. Jacolot,F. et al. (1991) Identification of the cytochrome P450 IIIA family as the enzymes involves in-the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol., 41, 1911-1919.
17. Crewe,H.K. et al. (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol., 53, 171-178.
18. Crewe,H.K. et al. (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: Formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos., 30, 869-874.
19. Coller,J.K. et al. (2004) Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. Br. J. Clin. Pharmacol., 57, 105-111.
20. Desta,Z. et al. (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther., 310, 1062-1075.
21. Dehal,S.S. et al. (1997) CYP2D6 catalyzes tamoxifen 4-hydroxy-lation in human liver. Cancer Res., 57, 3402-3406.
22. Boocock,D.J. et al. (2002) Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis, 23, 1897-1901.
23. Stearns,V. et al. (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst., 95, 1758-1764.
24. Johnson,M.D. et al. (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat., 85, 151-159.
25. Jin, Y. et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst., 97, 30-39.
26. Lim, Y.C. et al. (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother. Pharmacol., 55, 471-478.
27. Borgna,J.L. et al. (1981) Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem., 256, 859-868.
28. Coezy,E. et al. (1982) Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res., 42, 317-323.
29. Jordan, V.C. (1982) Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res. Treat., 2, 123-138.
30. Hukkanen,J. et al. (1998) Expression of cytochrome P450 genes encoding enzymes active in metabolism of tamoxifen in human uterine endometrium. Pharmacol. Toxicol., 82, 93-97.
31. Sarkar,M.A. et al. (2003) Expression and cyclic variability of CYP3A4 and CYP3A7 isoforms in human endometrium and cervix during the menstrual cycle. Drug Metab. Dispos., 31, 1-6.
32. Sharma,M. et al. (2003) Biotransformation of tamoxifen in a human endometrial explant culture model. Chem. Biol. Interact., 146 237-249.
33. Rebbeck,T.R. et al. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst., 90, 1225-1229.
34. Paris,P.L. et al. (1999) Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomarkers Prev., 8, 901-905.
35. Plummer,S.J. et al. (2003) CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 12, 928-932.
36. Tayeb,M.T. et al. (2002) CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol. Rep., 9, 653-655.
37. Tayeb,M.T. et al. (2003) CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br. J. Cancer, 88, 928-932.
38. Jernstrom,H. et al. (2001) Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol. Biomarkers Prev., 10, 377-384.
39. Fried,K.M. et al. (1994) Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J. Chromatogr. B Biomed Appl., 655, 261-268.
40. Poon,G.K. et al. (1995) Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab. Dispos., 21, 1119-1124.
41. Keshava,C. et al. (2004) CYP3A4 polymorphisms - potential risk factors for breast and prostate cancer: A HuGE review. Am. J. Epidemiol., 160, 825-841.
42. Potter,G.A. et al. (1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis, 15, 439-442.
43. Jarman,M. et al. (1995) The deuterium isotope effect for the a-hydroxylation of tamoxifen by rat liver microsomes accounts for the reduced genotoxicity of D5-ethyl tamoxifen. Carcinogenesis, 16 683-688.
44. Phillips,D.H. et al. (1996) Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products: Comparisons between human, rat and mouse hepatocytes. Carcinogenesis, 17 89-94.
45. Dasaradhi,L. et al. (1997) Identification of tamoxifen-DNA adducts formed by alpha-sulfate tamoxifen and alpha-acetoxytamoxifen. Chem. Res. Toxicol., 10, 189-196.
46. Carmichael,P.L. et al. (1999) Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis, 20, 339-342.
47. Carmichael,P.L. et al. (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res., 56, 1475-1479.
48. Hemminki,K. et al. (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res., 56, 4374-4377.
49. Shibutani,S. et al. (1999) Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol., 12, 646-653.
50. Shibutani,S. et al. (2000) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21, 1461-1467.
51. Phillips,D.H. (2001) Understanding the genotoxicity of tamoxifen? Carcinogenesis, 22, 839-849.
52. Kim,S.Y. et al. (2005) Formation of tamoxifen-DNA adducts in human endometrial explants exposed to alpha-hydroxytamoxifen. Chem. Res. Toxicol., 18, 889-895.
53. Amirimani,B. et al. (1999) Response: Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst., 91, 1588-1590.
54. Amirimani,B. et al. (2003) Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen., 42, 299-305.
55. Spurdle,A.B. et al. (2002) The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics, 355-366.
56. Rodriguez-Antona,C. et al. (2005) Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles: Biochem. Biophys. Res. Commun. 338, 299-305.
57. Ando,Y. et al. (1999) Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst., 91, 1587-1590.
58. Ball,S.E. et al. (1999) Population distribution and effects on drug-metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther., 66, 288-294.
59. Westlind,A. et al. (1999) Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem. Biophys. Res. Commun., 259, 201-205.
60. Kuehl,P. et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 27, 383-391.
61. Wandel,C. et al. (2000) CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin. Pharmacol. Ther., 68, 82-91.